CD36 and metabolic dysfunction-associated steatotic liver disease: Moreover, we firstly discovered that CD36 as a potential target of FV for NAFLD and then FV exerted pharmacologic effects against NAFLD partly by reducing the expression of CD36 to improve lipid metabolism and inflammation.